N¹-(benzo[d]thiazol-2-yl)ethane-1,2-diamine | 144580-67-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: N¹-(benzo[d]thiazol-2-yl)ethane-1,2-diamine
• 英文别名: N1-(benzo[d]thiazol-2-yl)ethane-1,2-diamine；N'-(1,3-benzothiazol-2-yl)ethane-1,2-diamine
• CAS: 144580-67-6
• 化学式: C₉H₁₁N₃S
• mdl: MFCD09042112
• 分子量: 193.272
• InChiKey: KDAQFKLDHWSEHK-UHFFFAOYSA-N

物化性质

• 沸点：
  338.7±44.0 °C(Predicted)
• 密度：
  1.324±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  79.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N¹-(benzo[d]thiazol-2-yl)ethane-1,2-diamine 、 3,4-二氯苯甲醛 在 sodium methylate 作用下， 以 甲醇 为溶剂， 反应 1.17h， 生成
  参考文献：
  名称：

  Preparation, antibacterial evaluation and preliminary structure–activity relationship (SAR) study of benzothiazol- and benzoxazol-2-amine derivatives

  摘要：

  In this study, a novel benzothiazol- and benzooxazol-2-amine scaffold with antibacterial activity was designed and synthesized. Preliminary structure-activity relationship analysis displayed that compound 8t with a 5,6-difluorosubstituted benzothiazole was found to be a potent inhibitor of Gram-positive pathogens, and exhibited some potential against drug-resistant bacteria and without cytotoxicity in therapeutic concentrations. In addition, molecular docking studies indicated that Staphylococcus aureus methionyl-tRNA synthetase might be the possible target of these compounds. Taken together, the present study provides an effective entry to the synthesis of a good lead for subsequent optimization and a new small molecule candidate drug for antibacterial therapeutics. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.03.079
• 作为产物：
  描述：

  2-氯苯并噻唑 在 potassium carbonate 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 N¹-(benzo[d]thiazol-2-yl)ethane-1,2-diamine
  参考文献：
  名称：

  Preparation, antibacterial evaluation and preliminary structure–activity relationship (SAR) study of benzothiazol- and benzoxazol-2-amine derivatives

  摘要：

  In this study, a novel benzothiazol- and benzooxazol-2-amine scaffold with antibacterial activity was designed and synthesized. Preliminary structure-activity relationship analysis displayed that compound 8t with a 5,6-difluorosubstituted benzothiazole was found to be a potent inhibitor of Gram-positive pathogens, and exhibited some potential against drug-resistant bacteria and without cytotoxicity in therapeutic concentrations. In addition, molecular docking studies indicated that Staphylococcus aureus methionyl-tRNA synthetase might be the possible target of these compounds. Taken together, the present study provides an effective entry to the synthesis of a good lead for subsequent optimization and a new small molecule candidate drug for antibacterial therapeutics. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.03.079

文献信息

• DIPEPTIDYL PEPTIDASE IV INHIBITOR
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1354882A1

  公开（公告）日：2003-10-22

  A compound represented by general formula (I):         A-B-D or a pharmacologically acceptable salt thereof.

  一个由通用式(I)表示的化合物：         A-B-D <其中 A代表取代或未取代的1-吡咯烷基、取代或未取代的3-噻唑烷基、取代或未取代的1-氧代-3-噻唑烷基等； B代表a)由-(C(R1)(R2))kCO-（其中k表示1至6的整数，R1和R2可以相同也可以不同，每个代表氢原子、羟基、卤素原子等）等的基团； D代表-U-V [其中U代表取代或未取代的哌嗪基团等，V代表-E-R7（其中E代表单键、-CO-、-C(=O)O-或-SO2-；R7代表氢原子、取代或未取代的烷基等）] >或其药理学上可接受的盐。
• Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines
  申请人：Pfizer Inc.

  公开号：US20040192698A1

  公开（公告）日：2004-09-30

  The present invention provides compounds of formula (I) 1 the prodrugs thereof, and the pharmaceutically acceptable salts of the compounds and prodrugs, wherein R a , R b , R 1 , and R 2 are as defined herein; pharmaceutical compositions thereof; and uses thereof.

  本发明提供了式(I)的化合物 1 的前药，以及所述化合物和前药的药学上可接受的盐，其中R a ，R b ，R 1 和R 2 如本文所定义；其药物组合物；以及其用途。
• [EN] SUBSTITUTED 2H-[1,2,4]TRIAZOLO[4,3-A]PYRAZINES AS GSK-3 INHIBITORS<br/>[FR] 2H-[1,2,4]TRIAZOLO[4,3-A]PYRAZINES SUBSTITUEES EN TANT QU'INHIBITEURS DE LA GSK-3
  申请人：PFIZER PROD INC

  公开号：WO2005035532A1

  公开（公告）日：2005-04-21

  The invention relates to compounds of formula (I) prodrugs thereof, and the pahrmaceutically acceptabel salts of the compounds and prodrugs, wherein Ra, Rb, R1 and R2 are as defined herein; pharmaceutical compositions thereof; and uses thereof.

  这项发明涉及到式(I)化合物及其前药，以及该化合物和前药的药用可接受盐，其中Ra、Rb、R1和R2如本文所定义；药物组合物；以及它们的用途。
• SUBSTITUTED BENZOTHIAZOLE AND BENZOXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF DPP-1
  申请人：Jordan Alfonzo D.

  公开号：US20110152287A1

  公开（公告）日：2011-06-23

  The present invention is directed to substituted benzothiazole and benzoxazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by DPP-1.

  本发明涉及替代苯并噻唑和苯并噁唑衍生物，包含它们的药物组合物以及它们在通过DPP-1调节的疾病和症状治疗中的应用。
• Dipeptidylpeptidase-IV inhibitor
  申请人：——

  公开号：US20040180925A1

  公开（公告）日：2004-09-16

  A compound represented by general formula (I): A-B-D or a pharmacologically acceptable salt thereof.

  通式(I)所表示的化合物：A-B-D，其中，A代表取代或未取代的1-吡咯烷基、取代或未取代的3-噻唑烷基、取代或未取代的1-氧代-3-噻唑烷基等；B代表a)由—(C(R1)(R2))kCO—（其中k为1到6的整数，R1和R2可以相同也可以不同，分别代表氢原子、羟基、卤素原子等）等组成的基团；D代表—U—V [其中U代表取代或未取代的哌嗪基等，V代表-E-R7（其中E代表单键、—CO—、—C(═O)O—或—SO2—；R7代表氢原子、取代或未取代的烷基等）]或其药理学上可接受的盐。